Novo Nordisk Strikes Deal for Late-Stage Hypertension & Kidney Disease Drug
Kort samengevat
The KBP Biosciences drug Novo Nordisk is acquiring has reached Phase 3 testing as a potential treatment for uncontrolled hypertension and advanced chronic kidney disease. It’s the latest in a string of business deals aimed at expanding the Novo Nordisk pipeline beyond diabetes.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij MedCity News.
Lees het volledige bericht ↗